This “Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Juvenile Rheumatoid Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The most common signs and symptoms of juvenile idiopathic arthritis (JIA) are joint pain, swelling, stiffness and limited mobility, often worse in the morning or after naps. Joints may appear red, warm and tender to the touch. Some children may experience high fever, swollen lymph nodes, rash on the trunk, fatigue, and appetite loss and eye inflammation. Symptoms can vary in severity and duration, with some children only having symptoms for a few months while others have them for many years. The number and type of joints affected depends on the specific subtype of JIA.
The diagnosis of juvenile idiopathic arthritis (JIA) is based on the child's medical history, physical examination, and laboratory tests. Doctors look for joint pain, swelling, stiffness, and limited range of motion that has lasted for at least 6 weeks in a child under 16 years old. They may order blood tests to check for markers of inflammation like erythrocyte sedimentation rate and C-reactive protein, as well as autoantibodies like rheumatoid factor and antinuclear antibodies. Imaging tests like X-rays or MRI scans can help rule out other conditions and detect joint damage. Since there is no single definitive test for JIA, the diagnosis is made by excluding other potential causes of the child's symptoms.
The treatment of juvenile idiopathic arthritis (JIA) aims to control pain, preserve joint function, and prevent long-term damage. The first-line medications are nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to reduce inflammation. Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate are often added if NSAIDs alone are insufficient. For severe cases, corticosteroids or biologic drugs that target specific inflammatory pathways may be used. Physical therapy is crucial to maintain joint mobility and muscle strength.
'Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Juvenile Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Juvenile Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Juvenile Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Juvenile Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
This product will be delivered within 2 business days.
Juvenile Rheumatoid Arthritis: Understanding
Juvenile Rheumatoid Arthritis: Overview
Juvenile idiopathic arthritis (JIA), formerly known as juvenile rheumatoid arthritis, is the most common type of arthritis in children under 16. JIA is an autoimmune disorder where the body's immune system mistakenly attacks its own cells and tissues, causing inflammation in the joints. The exact causes are unknown, but both heredity and environmental factors seem to play a role, with a genetic tendency combined with a trigger like a virus causing the immune system to go awry. JIA can affect any joint, leading to persistent pain, swelling, stiffness and limited mobility, with symptoms varying in duration from a few months to many years. Treatment focuses on controlling pain and inflammation, improving function, and preventing joint damage.The most common signs and symptoms of juvenile idiopathic arthritis (JIA) are joint pain, swelling, stiffness and limited mobility, often worse in the morning or after naps. Joints may appear red, warm and tender to the touch. Some children may experience high fever, swollen lymph nodes, rash on the trunk, fatigue, and appetite loss and eye inflammation. Symptoms can vary in severity and duration, with some children only having symptoms for a few months while others have them for many years. The number and type of joints affected depends on the specific subtype of JIA.
The diagnosis of juvenile idiopathic arthritis (JIA) is based on the child's medical history, physical examination, and laboratory tests. Doctors look for joint pain, swelling, stiffness, and limited range of motion that has lasted for at least 6 weeks in a child under 16 years old. They may order blood tests to check for markers of inflammation like erythrocyte sedimentation rate and C-reactive protein, as well as autoantibodies like rheumatoid factor and antinuclear antibodies. Imaging tests like X-rays or MRI scans can help rule out other conditions and detect joint damage. Since there is no single definitive test for JIA, the diagnosis is made by excluding other potential causes of the child's symptoms.
The treatment of juvenile idiopathic arthritis (JIA) aims to control pain, preserve joint function, and prevent long-term damage. The first-line medications are nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen to reduce inflammation. Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate are often added if NSAIDs alone are insufficient. For severe cases, corticosteroids or biologic drugs that target specific inflammatory pathways may be used. Physical therapy is crucial to maintain joint mobility and muscle strength.
'Juvenile Rheumatoid Arthritis - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Juvenile Rheumatoid Arthritis pipeline landscape is provided which includes the disease overview and Juvenile Rheumatoid Arthritis treatment guidelines. The assessment part of the report embraces, in depth Juvenile Rheumatoid Arthritis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Juvenile Rheumatoid Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Juvenile Rheumatoid Arthritis R&D. The therapies under development are focused on novel approaches to treat/improve Juvenile Rheumatoid Arthritis.Juvenile Rheumatoid Arthritis Emerging Drugs Chapters
This segment of the Juvenile Rheumatoid Arthritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.Juvenile Rheumatoid Arthritis Emerging Drugs
Baricitinib: Eli Lilly and Company
Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signaling that is frequently over-activated in autoimmune disorders such as rheumatoid arthritis. By blocking the actions of JAK1/2, baricitinib disrupts the activation of downstream signaling molecules and proinflammatory mediators. Currently, the drug is in the Phase III stage of clinical trial evaluation for the treatment of Juvenile Rheumatoid Arthritis.MP-1032: MetrioPharm
MetrioPharm's drug candidate MP1032 represents a radically new concept in anti-inflammatory and corticosteroid-sparing therapy. MP1032 in combination with ultra-low dose corticosteroids has the potential to replace the current high dose corticosteroids (cortisone-based) therapy - with increased efficacy and reduced side effects. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Juvenile Rheumatoid Arthritis.Juvenile Rheumatoid Arthritis: Therapeutic Assessment
This segment of the report provides insights about the different Juvenile Rheumatoid Arthritis drugs segregated based on following parameters that define the scope of the report, such as:Major Players in Juvenile Rheumatoid Arthritis
There are approx. 20+ key companies which are developing the therapies for Juvenile Rheumatoid Arthritis. The companies which have their Juvenile Rheumatoid Arthritis drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.Phases
The report covers around 21+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Juvenile Rheumatoid Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.Juvenile Rheumatoid Arthritis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Juvenile Rheumatoid Arthritis therapeutic drugs key players involved in developing key drugs.Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Juvenile Rheumatoid Arthritis drugs.Juvenile Rheumatoid Arthritis Report Insights
- Juvenile Rheumatoid Arthritis Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Juvenile Rheumatoid Arthritis Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Juvenile Rheumatoid Arthritis drugs?
- How many Juvenile Rheumatoid Arthritis drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Juvenile Rheumatoid Arthritis?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Juvenile Rheumatoid Arthritis therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Juvenile Rheumatoid Arthritis and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Eli Lilly and Company
- MetrioPharm
- Amgen
- Sunshine Guojian Pharmaceutical
- GENERIUM Pharmaceuticals
- UCB
Key Products
- Baricitinib
- MP-1032
- Apremilast
- SSGJ-613
- GNR 086
- Certolizumab
This product will be delivered within 2 business days.
Table of Contents
IntroductionExecutive SummaryJuvenile Rheumatoid Arthritis- The Publisher's Analytical PerspectiveJuvenile Rheumatoid Arthritis Key CompaniesJuvenile Rheumatoid Arthritis Key ProductsJuvenile Rheumatoid Arthritis- Unmet NeedsJuvenile Rheumatoid Arthritis- Market Drivers and BarriersJuvenile Rheumatoid Arthritis- Future Perspectives and ConclusionJuvenile Rheumatoid Arthritis Analyst ViewsJuvenile Rheumatoid Arthritis Key CompaniesAppendix
Juvenile Rheumatoid Arthritis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Baricitinib: Eli Lilly and Company
Mid Stage Products (Phase II)
Drug name: Company name
Early Stage Products (Phase I)
MP-1032: MetrioPharm
Preclinical and Discovery Stage Products
Drug name: Company name
Inactive Products
List of Table
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Eli Lilly and Company
- MetrioPharm
- Amgen
- Sunshine Guojian Pharmaceutical
- GENERIUM Pharmaceuticals
- UCB
